Baylor Turns Food Bacteria Into Colorectal Cancer Fighter

Scientists just turned one of our food safety fears into a cancer-fighting hero.

Researchers at Baylor University have successfully modified Listeria monocytogenes, the bacteria that causes food poisoning, to carry cancer-killing proteins directly into colorectal tumor cells. Their findings, published in the prestigious journal Cell Chemical Biology, show promising results that could reshape how we fight the second-deadliest cancer in America.

Dr. Michael VanNieuwenhze and his team asked a simple but brilliant question: What if we could attach a cancer-killing toxin to bacteria and let it ride along into cancer cells? They paired Listeria with saporin, a protein that destroys cancer cells once inside them, creating a microscopic delivery system that worked better than either component alone.

The choice of Listeria wasn't random. Unlike most bacteria, it naturally penetrates human cells, giving it access to spaces where cancer hides. By genetically modifying it for safety while preserving its cell-penetrating superpower, the team created what doctoral student Wyatt Paulishak calls "a drug-delivery vehicle" with built-in cancer-fighting abilities.

The research team used fluorescent imaging to prove the saporin actually attached to the bacteria and reached its target. Then came the real test: mice with cancer showed significantly increased tumor death when treated with the bacteria-toxin combination compared to standard approaches.

Colorectal cancer killed more Americans than any cancer except lung cancer in 2025, making new treatment strategies desperately needed. Current therapies often struggle to deliver drugs precisely where they're needed without harming healthy tissue.

The Ripple Effect

This breakthrough opens doors beyond colorectal cancer. The bacteria-as-courier approach could potentially work for other cancers where targeted drug delivery remains a challenge. Because Listeria naturally travels through the digestive system, future treatments might be taken orally rather than through injections or infusions, making cancer therapy more accessible and less invasive.

VanNieuwenhze's team is already looking ahead to genetic strategies that could make the process even safer and more effective at scale. Doctoral student Jianan Lyu notes that proving delivery was possible marked a crucial milestone, but turning laboratory success into actual therapeutics requires additional steps.

The research represents years of work building on studies dating back to 1994, when scientists first explored using modified bacteria against cancer. What makes this approach special is the chemical attachment method, which multiplies the bacteria's natural anti-cancer properties while maintaining its ability to reach tumor cells safely.

The team's success shows how reimagining something familiar in a new context can lead to genuine medical progress. Today's food safety concern could become tomorrow's life-saving treatment, bringing hope to the hundreds of thousands of people diagnosed with colorectal cancer each year.